Alopecia Areata Trial Counts Need to Separate Teenagers From Younger Children

A new Journal of the American Academy of Dermatology paper, “Pediatric Representation and Demographic Reporting in Alopecia Areata Clinical Trials,” is listed online with an October 8, 2026 publication date. Its full text was unavailable through the linked publisher page during reporting, so its search strategy, included trials and numerical findings cannot yet be independently assessed. That limitation matters especially for a subject where a single pediatric category can join patients with very different evidence behind their treatment options.

The key cutoff is age 12. The FDA approved Pfizer’s ritlecitinib, sold as Litfulo, for severe alopecia areata in adults and adolescents 12 and older on June 23, 2023. Its drug-trial snapshot describes it as the first FDA-approved treatment for severe alopecia areata in that adolescent group. Baricitinib and deuruxolitinib have adult-only alopecia areata indications. A trial census that treats all participants under 18 as one group can therefore overstate the direct evidence available to a younger child.

For children ages 6 to under 12, the public record currently illustrates how preliminary the evidence remains. A completed Pfizer pharmacokinetic study, NCT05650333, enrolled 15 children and administered ritlecitinib for seven days. It was designed to measure drug exposure and inform dosing, not to establish durable hair regrowth or long-term safety. FDA’s 2023 approval letter required a randomized, placebo-controlled study in that age band, with expected completion in May 2027. The agency waived a study requirement below age 6 as “impossible or highly impracticable,” language about study feasibility that does not measure disease burden.

Enrollment demographics add a second question: whether the available reports can show who entered trials. A 2023 systematic review of randomized JAK-inhibitor alopecia areata trials found five of 12 eligible studies lacked race and ethnicity data complete enough for inclusion. Across six included studies, involving 1,690 participants, 59.9 percent were reported as White, 28.0 percent as Asian and 8.1 percent as Black; only one trial reported Hispanic or Latino ethnicity. None reported efficacy analyses by race or ethnicity. Those omissions prevent readers from moving from an enrollment table to a well-supported claim about comparable outcomes across groups.

A benchmark for representation also needs care. The review compared trial demographics with an older National Alopecia Areata Registry, while newer pediatric evidence points in a different direction. A Northern California cohort of 598,067 children found higher alopecia areata prevalence among Hispanic, Asian or Pacific Islander, and Black children than among non-Hispanic White children. Geography, referral patterns, access to specialty care and trial sites can all shape the populations that appear in registries and trials. The concrete test for the forthcoming paper will be whether it separates ages 12 to 17 from children under 12, identifies missing demographic fields, and says which source supplied each number. A 15-person, seven-day dosing study is a useful detail to keep in view when the word “pediatric” appears in a trial headline.